Posted by Michael Wonder on 17 May 2018
NICE backs Roche’s Tecentriq for pre-treated bladder cancer
17 May 2018 - Roche’s Tecentriq will be routinely available on the NHS in England and Wales to patients with advanced, pre-treated bladder cancer, following a nod from cost-regulators.
The National Institute for Health and Care Excellence is endorsing the drug’s use in patients whose disease has progressed during or after treatment with platinum-containing chemotherapy.
The guidelines stipulate that treatment with Tecentriq (atezolizumab) is stopped after two years of uninterrupted treatment or earlier, or if the disease progresses.
